# Eugenio Cersosimo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3627677/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 28<br>papers | 2,197<br>citations | 567144<br>15<br>h-index | 501076<br>28<br>g-index |
| 29<br>all docs | 29<br>docs citations | 29<br>times ranked | 3707<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. Gastroenterology, 2007, 133, 496-506. | 0.6 | 500 |
| 2 | Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes/Metabolism Research and Reviews, 2006, 22, 423-436. | 1.7 | 373 |
| 3 | Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. Diabetes, 2008, 57, 2595-2602. | 0.3 | 319 |
| 4 | Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes. Diabetes, 2003, 52, 1364-1370. | 0.3 | 265 |
| 5 | Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications. Current Diabetes Reviews, 2014, 10, 2-42. | 0.6 | 179 |
| 6 | Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E846-E852. | 1.8 | 144 |
| 7 | Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. Diabetes, 2017, 66, 1999-2006. | 0.3 | 67 |
| 8 | Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. Diabetes Care, 2013, 36, 2756-2762. | 4.3 | 52 |
| 9 | Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. Diabetes, 2018, 67, 1182-1189. | 0.3 | 44 |
| 10 | Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes, Obesity and Metabolism, 2018, 20, 497-507. | 2.2 | 33 |
| 11 | Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 1234-1241. | 4.3 | 30 |
| 12 | Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care, 2021, 44, 433-439. | 4.3 | 29 |
| 13 | Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. Diabetes, 2020, 69, 681-688. | 0.3 | 23 |
| 14 | Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1256-1262. | 1.8 | 22 |
| 15 | Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. American Journal of Physiology - Cell Physiology, 2012, 302, C652-C657. | 2.1 | 22 |
| 16 | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<scp>EDICT</scp>). Diabetes, Obesity and Metabolism, 2022, 24, 899-907. | 2.2 | 15 |
| 17 | Comprehensive assessment of postischemic vascular reactivity in Hispanic children and adults with and without diabetes mellitus. Pediatric Diabetes, 2006, 7, 329-335. | 1.2 | 13 |
| 18 | Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. Current Diabetes Reviews, 2019, 15, 314-327. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation. Physiological Reports, 2014, 2, e12123. | 0.7 | 10 |
| 20 | Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3226-3233. | 1.8 | 10 |
| 21 | Glucose lowering and vascular protective effects of cycloset added to <scp>GLP</scp>â€1 receptor agonists in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2018, 1, e00034. | 1.0 | 9 |
| 22 | Impaired left ventricular diastolic function in T2<scp>DM</scp> patients is closely related to glycemic control. Endocrinology, Diabetes and Metabolism, 2018, 1, e00014. | 1.0 | 6 |
| 23 | Anti-inflammatory and anti-proliferative action of adiponectin mediated by insulin signaling cascade in human vascular smooth muscle cells. Molecular Biology Reports, 2020, 47, 6561-6572. | 1.0 | 6 |
| 24 | Effects of Î²-adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E792-E797. | 1.8 | 5 |
| 25 | Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Diabetes Care, 2022, 45, 1372-1380. | 4.3 | 4 |
| 26 | Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care, 2020, 43, 2519-2527. | 4.3 | 3 |
| 27 | Effects of a metabolic syndrome selfâ€management programme for women with preâ€diabetes. Focus on Alternative and Complementary Therapies, 2015, 20, 74-80. | 0.1 | 2 |
| 28 | Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. Diabetes Spectrum, 2021, 34, 248-256. | 0.4 | 1 |